Impact BioMedical Inc.

What they do

Impact Biomedical discovers and patents technologies for human healthcare, then seeks licensing, co-development, and joint venture partners to commercialize them. Its principal pipeline includes Linebacker (oncology/inflammatory/neurology), Laetose (sugar reduction/glycemic control), 3F functional fragrances, and Equivir (antiviral supplements). Operations are conducted through majority-owned subsidiaries Global BioLife, Impact BioLife Science, Global BioMedical, and Sweet Sense. The company has no meaningful product revenue and is primarily dependent on future milestone and royalty payments from licensees.

Revenue drivers

• Linebacker — Licensed to ProPhase Laboratories for worldwide development; potential future milestone and royalty payments. No revenue reported for this segment.
• Laetose — Patented sugar-reduction formulation; seeking commercialization partners. No revenue reported.
• 3F Functional Fragrance Formulation — Partnered with Chemia Corporation for development. No revenue reported.

Recent performance

For fiscal 2025, Impact Biomedical reported revenue of $32,000 and a net loss of $-11.8 million, diluted EPS $-0.38. Operating cash flow was $-1.9 million in 2025, improving from $-2.9 million in 2024. Quarterly revenue has been minimal and volatile: $7,000 (June 2025), $18,000 (Sept 2025), $7,000 (Mar 2026), and $3,000 (June 2026). At June 30, 2026, total assets were $16.7 million, liabilities $2.7 million, and shareholder equity $10.8 million; cash was just $20,000 as of March 31, 2026.

Strategy

The company's business model is partnering with pharmaceutical and consumer packaged goods companies to commercialize technologies in exchange for milestone and royalty payments. It is actively seeking partners for Laetose and 3F worldwide. Subsidiaries are used to own and operate assets. Management continues to evaluate new technologies to add to the portfolio.

Risks

• Liquidity risk — Cash and equivalents were only $20,000 as of March 31, 2026, and the company continues to generate negative operating cash flow, raising substantial doubt about its ability to fund ongoing operations.
• Limited revenue — Annual revenue has been under $100,000 in recent years, and quarterly revenue is minimal, indicating no commercial products are generating significant sales.
• Dependence on licensing partners — Most pipeline assets (e.g., Linebacker) are licensed to third parties, and the company relies on their development and commercialization efforts to generate any future milestone/royalty income.
• Intellectual property risk — The company's success depends on protecting its patents; failure could lead to lost revenue and material harm to operations.

Outlook

Management has not provided specific forward-looking financial guidance. The company plans to continue seeking partners to develop and commercialize its technologies (Laetose, 3F, Linebacker). It faces significant funding constraints and may need to raise capital. Recent 8-K filings indicate the company has entered several material agreements, which may suggest ongoing partnering activity.